Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis
Cholesterol 7 alpha-hydroxylase (CYP7A1, EC1.14) is the first and rate-limiting enzyme in the classic bile acid synthesis pathway. Much progress has been made in understanding the transcriptional regulation of CYP7A1 gene expression and the underlying molecular mechanisms of bile acid feedback regul...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
KeAi Communications Co., Ltd.
2020-06-01
|
Series: | Liver Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2542568420300210 |
id |
doaj-45cf5ebeaf3b4baeaa318bc4e8a59a7f |
---|---|
record_format |
Article |
spelling |
doaj-45cf5ebeaf3b4baeaa318bc4e8a59a7f2021-04-02T17:38:11ZengKeAi Communications Co., Ltd.Liver Research2542-56842020-06-01424763Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesisJohn Y.L. Chiang0Jessica M. Ferrell1Corresponding author.; Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH, USADepartment of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH, USACholesterol 7 alpha-hydroxylase (CYP7A1, EC1.14) is the first and rate-limiting enzyme in the classic bile acid synthesis pathway. Much progress has been made in understanding the transcriptional regulation of CYP7A1 gene expression and the underlying molecular mechanisms of bile acid feedback regulation of CYP7A1 and bile acid synthesis in the last three decades. Discovery of bile acid-activated receptors and their roles in the regulation of lipid, glucose and energy metabolism have been translated to the development of bile acid-based drug therapies for the treatment of liver-related metabolic diseases such as alcoholic and non-alcoholic fatty liver diseases, liver cirrhosis, diabetes, obesity and hepatocellular carcinoma. This review will provide an update on the advances in our understanding of the molecular biology and mechanistic insights of the regulation of CYP7A1 in bile acid synthesis in the last 40 years.http://www.sciencedirect.com/science/article/pii/S2542568420300210Cholesterol 7 alpha-hydroxylase (CYP7A1)Bile acid metabolismFarnesoid X receptor (FXR)Takeda G protein-coupled receptor 5 (TGR5)Bile acid receptorsLiver metabolism |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
John Y.L. Chiang Jessica M. Ferrell |
spellingShingle |
John Y.L. Chiang Jessica M. Ferrell Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis Liver Research Cholesterol 7 alpha-hydroxylase (CYP7A1) Bile acid metabolism Farnesoid X receptor (FXR) Takeda G protein-coupled receptor 5 (TGR5) Bile acid receptors Liver metabolism |
author_facet |
John Y.L. Chiang Jessica M. Ferrell |
author_sort |
John Y.L. Chiang |
title |
Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis |
title_short |
Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis |
title_full |
Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis |
title_fullStr |
Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis |
title_full_unstemmed |
Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis |
title_sort |
up to date on cholesterol 7 alpha-hydroxylase (cyp7a1) in bile acid synthesis |
publisher |
KeAi Communications Co., Ltd. |
series |
Liver Research |
issn |
2542-5684 |
publishDate |
2020-06-01 |
description |
Cholesterol 7 alpha-hydroxylase (CYP7A1, EC1.14) is the first and rate-limiting enzyme in the classic bile acid synthesis pathway. Much progress has been made in understanding the transcriptional regulation of CYP7A1 gene expression and the underlying molecular mechanisms of bile acid feedback regulation of CYP7A1 and bile acid synthesis in the last three decades. Discovery of bile acid-activated receptors and their roles in the regulation of lipid, glucose and energy metabolism have been translated to the development of bile acid-based drug therapies for the treatment of liver-related metabolic diseases such as alcoholic and non-alcoholic fatty liver diseases, liver cirrhosis, diabetes, obesity and hepatocellular carcinoma. This review will provide an update on the advances in our understanding of the molecular biology and mechanistic insights of the regulation of CYP7A1 in bile acid synthesis in the last 40 years. |
topic |
Cholesterol 7 alpha-hydroxylase (CYP7A1) Bile acid metabolism Farnesoid X receptor (FXR) Takeda G protein-coupled receptor 5 (TGR5) Bile acid receptors Liver metabolism |
url |
http://www.sciencedirect.com/science/article/pii/S2542568420300210 |
work_keys_str_mv |
AT johnylchiang uptodateoncholesterol7alphahydroxylasecyp7a1inbileacidsynthesis AT jessicamferrell uptodateoncholesterol7alphahydroxylasecyp7a1inbileacidsynthesis |
_version_ |
1721553666737963008 |